ClinicalTrials.gg

TargetBeta

IL12B

interleukin 12B · also CLMF, IL-12B, NKSF, CLMF2 · Immunoglobulin like domain containing

4 programs in company-led studies act on IL12B, from 4 companies: 0 in phase 3, 3 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
guselkumabruleJohnson & Johnsonphase 46019 runningIL23AChEMBL
risankizumabruleAbbViephase 46816 runningIL23AChEMBL
mirikizumabruleEli Lillyphase 4367 runningIL23AChEMBL
PF-07261271Pfizerphase 110 runningTNFSF15the company's pipeline

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.